Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer

Cancer

Volumn 118, Issue 16, 2012, Pages 3899-3910

  Sakakibara, Masahiro ^a   Fujimori, Toshihiko ^a   Miyoshi, Tetsutaro ^a   Nagashima, Takeshi ^a   Fujimoto, Hiroshi ^a   Suzuki, Hiroshi Tiberu ^a   Ohki, Yohsuke ^a   Fushimi, Koya ^a   Yokomizo, Jissei ^a   Nakatani, Yukio ^a   Miyazaki, Masaru ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

breast cancer; cancer stem cell; chemotherapy; metastasis; multivariate analysis

Indexed keywords

ALDEHYDE DEHYDROGENASE; ALDEHYDE DEHYDROGENASE ISOENZYME 1; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PACLITAXEL; PROGESTERONE RECEPTOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; BREAST SURGERY; CANCER ADJUVANT THERAPY; CANCER CELL; CANCER GRADING; CANCER TISSUE; CYTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NEEDLE BIOPSY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE;

AXILLA; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; ISOENZYMES; LYMPH NODES; LYMPHATIC METASTASIS; MIDDLE AGED; RETINAL DEHYDROGENASE;

EID: 84864649893     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.26725     Document Type: Article

References (35)

1. Lapidot T, Sirard C, Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature. 1994; 367: 645-648.
2. Reya T, Morrison SJ, Clarke MF, Weissman IL,. Stem cells, cancer, and cancer stem cells. Nature. 2001; 414: 105-111.
3. Lobo NA, Shimono Y, Qian D, Clarke MF,. The biology of cancer stem cells. Annu Rev Cell Dev Biol. 2007; 23: 675-699.
4. Wicha MS, Liu S, Dontu G,. Cancer stem cells: an old idea-a paradigm shift. Cancer Res. 2006; 66: 1883-1890; discussion 1895-1886.
5. Ward RJ, Dirks PB,. Cancer stem cells: at the headwaters of tumor development. Annu Rev Pathol. 2007; 2: 175-189.
6. Prince ME, Sivanandan R, Kaczorowski A, et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A. 2007; 104: 973-978.
7. Smalley M, Ashworth A,. Stem cells and breast cancer: a field in transit. Nat Rev Cancer. 2003; 3: 832-844.
8. Jordan CT, Guzman ML, Noble M,. Cancer stem cells. N Engl J Med. 2006; 355: 1253-1261.
9. Stingl J, Caldas C,. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat Rev Cancer. 2007; 7: 791-799.
10. Visvader JE, Lindeman GJ,. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8: 755-768.
11. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF,. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003; 100: 3983-3988.
12. Singh SK, Clarke ID, Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003; 63: 5821-5828.
13. O'Brien CA, Pollett A, Gallinger S, Dick JE,. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature. 2007; 445: 106-110.
14. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007; 445: 111-115.
15. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007; 67: 1030-1037.
16. Secchi GC,. Cancer chemotherapy. Ann Ital Med Int. 1990; 5 (3 pt 3): 288-295.
17. Leonard GD, Fojo T, Bates SE,. The role of ABC transporters in clinical practice. Oncologist. 2003; 8: 411-424.
18. Song LL, Miele L,. Cancer stem cells-an old idea that's new again: implications for the diagnosis and treatment of breast cancer. Expert Opin Biol Ther. 2007; 7: 431-438.
19. Li X, Lewis MT, Huang J, et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst. 2008; 100: 672-679.
20. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell. 2007; 1: 555-567.
21. Tanei T, Morimoto K, Shimazu K, et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin Cancer Res. 2009; 15: 4234-4241.
22. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009; 69: 1302-1313.
23. Lawson JC, Blatch GL, Edkins AL,. Cancer stem cells in breast cancer and metastasis. Breast Cancer Res Treat. 2009; 118: 241-254.
24. Hortobagyi GN,. Treatment of breast cancer. N Engl J Med. 1998; 339: 974-984.
25. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol. 1998; 16: 2672-2685.
26. Abrial SC, Penault-Llorca F, Delva R, et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat. 2005; 94: 255-263.
27. Kuerer HM, Newman LA, Smith TL, et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 1999; 17: 460-469.
28. Hennessy BT, Hortobagyi GN, Rouzier R, et al. Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol. 2005; 23: 9304-9311.
29. Sakakibara M, Nagashima T, Kadowaki M, et al. Clinical significance of axillary microresiduals after neoadjuvant chemotherapy in breast cancer patients with cytologically proven metastases. Ann Surg Oncol. 2009; 16: 2470-2478.
30. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347: 1999-2009.
31. Buzdar AU,. Role of biologic therapy and chemotherapy in hormone receptor- and HER2-positive breast cancer. Ann Oncol. 2009; 20: 993-999.
32. Kaufmann M, Pusztai L,; Biedenkopf Expert Panel Members. Use of standard markers and incorporation of molecular markers into breast cancer therapy: consensus recommendations from an international expert panel. Cancer. 2011; 117: 1575-1582.
33. Buzdar AU, Ibrahim NK, Francis D, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005; 23: 3676-3685.
34. Fisher B, Bauer M, Wickerham DL, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. an NSABP update. Cancer. 1983; 52: 1551-1557.
35. Carter CL, Allen C, Henson DE,. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer. 1989; 63: 181-187.